PolyU Marshall Research Centre for Medical Microbial Biotechnology
PolyU Marshall Research Centre for Medical Microbial Biotechnology aims to advance the diagnosis and treatment of bacterial infections. The Centre is firmly committed to fostering international collaboration, thereby strengthening the global impact of its work in medical microbiology. It also places a strong emphasis on the development of novel antibiotics to combat the escalating threat of antimicrobial resistance.
Read MoreHide
Research Centre for Carbon-Strategic Catalysis
The establishment of the Research Centre for Carbon-Strategic Catalysis (RC-CSC) aims to supply a platform that can strengthen the research collaborations and efforts in PolyU to achieve more impactful outputs on the advanced catalyst design and synthesis for the sustainable energy development strategies. The Hong Kong government has announced that Hong Kong would strive to achieve carbon neutrality before 2050. Currently, electricity generation was the largest source of carbon emissions, accounting for about 66% of the total emissions in Hong Kong, followed by transport (about 18%) and waste (about 7%, mainly from landfills). Therefore, it is an extremely challenging target to achieve carbon neutrality before 2050, which requires all the joint efforts and participation from all the universities of Hong Kong to formulate the proactive, forward-looking and targeted strategy and platforms.
Read MoreHide
Lo Ka Chung Research Centre for Natural Anti-Cancer Drug Development
The Lo Ka Chung Research Centre for Natural Anti-Cancer Drug Development is established in late 2006. Through out the years the centre has carried out pioneering research in natural anti-cancer drugs, and has contributed directly to the community by promoting educational training. So far, the centre has developed two novel drugs to treat cancer. The second drug (BCA-PEG20), which represents a new paradigm for treating many cancer types, has been awarded the Prize of the State of Geneva and Gold Medal with Jury’s Commendation at the 37th International Exhibition of Inventions, New Techniques and Products of Geneva in 2009. We have formulated the drug with state-of-the-art DNA technology and protein modification and significantly prolonged its half-life for therapeutic use. The use of this new drug will open up many new opportunities for treating different types of cancers.
Read MoreHide
PolyU-Daya Bay Technology and Innovation Research Institute
The PolyU-Daya Bay Technology and Innovation Research Institute has four key research areas, namely new materials and new energy, green chemistry and sustainable catalysis, spatial computing and imaging, and green and smart manufacturing. These areas address current industry needs while paving the way for future advancements. The institute aims to become a model of cooperation between Huizhou and Hong Kong. By leveraging the solid foundation and policy support of the Daya Bay Economic and Technological Development Zone, it will introduce Hong Kong’s expertise to Huizhou’s industrial landscape. This will accelerate the establishment of green and low-carbon systems, enhance manufacturing development, and build competitive industrial clusters in petrochemical energy, new materials, and electronic information.
Read MoreHide
PolyU-Zhongshan Technology and Innovation Research Institute
The PolyU-Zhongshan Technology and Innovation Research Institute is dedicated to advancing research in biomedicine. This partnership between PolyU and the Zhongshan Municipal People’s Government (Zhongshan Government) marks a significant milestone in collaboration in biomedicine between the two cities, further strengthening PolyU’s presence in the Mainland. The Institute will focus on four major areas in the biomedicine and healthcare industries, including Innovative diagnostic drugs and medical devices, New biomedicine materials, Spinal health biomedical engineering, and Animal influenza vaccine development.
Read MoreHide
Henry Cheng Research Laboratory for Drug Development
Located on the seventh floor of the Lee Shau Kee Building on the PolyU campus, the "Henry Cheng Research Laboratory for Drug Development" has a total floor area of 537 square metres. The Laboratory provides state-of-the-art equipment including flow cytometer, confocal microscopy, thermos fisher scientific system and a high-performance liquid chromatography machine, which serves as a technology platform for an excellent research team of chemistry and biology experts to work together towards the common goal of developing new drugs for the benefit of mankind.
Read MoreHide
Advanced Therapy Product Laboratory
The PolyU Advanced Therapy Product (ATP) Laboratory is a Pharmaceutical Inspection Co-operation Scheme’s Good Manufacturing Practice (PIC/S GMP)-compliant facility, focusing on clinical research in immunotherapy, cell therapy, gene therapy and regenerative medicine. Equipped with a Production Site, Quality Control Laboratory and Training Laboratory, the Laboratory will serve as a robust platform for the development and clinical application of local ATPs. The ATP team, in collaboration with scientific research enterprises, the biopharmaceutical industry, and academic institutions, will focus on clinical trials for spinal cord injury patients during its first phase of work. It will make use of human leukocyte antigen (HLA)-matched umbilical cord blood received from the industry partner to produce umbilical cord blood-derived mononuclear cells. Quality control and product packaging procedures will also be performed. PIC/S GMP-compliant final products will then be sent to the hospitals for transplantation in patients.
Read MoreHide
PolyU-Axis Therapeutics Joint Laboratory for Immunotherapy
PolyU has entered into a formal collaboration with Axis Therapeutics (Axis) to foster cancer immunotherapy research and development, with the aim of improving cancer treatment for patients in Hong Kong. The establishment of the PolyU-Axis Therapeutics Joint Laboratory for Immunotherapy facilitates clinical trials of new T-cell receptor therapy using the newly established clinical Current Good Manufacturing Practice (cGMP) facility at PolyU, which is compliant with the GMP Guide for the Advanced Therapy Products (ATPs), and the development of at least 30 new targeting agents against novel T-cell targets in cancer immunotherapy.
Read MoreHide
